Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

45.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential mechanisms and therapeutic prospects of the association between <i>Helicobacter pylori</i> infection and metabolic dysfunction-associated steatohepatitis.

World journal of hepatology·2025
Same author

Clinical features and prognostic analysis of posterior reversible encephalopathy syndrome in children.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience·2022
Same author

Alkaline activation of endogenous latent TGFβ1 by an injectable hydrogel directs cell homing for in situ complex tissue regeneration.

Bioactive materials·2022
Same author

Research Progress in Antineoplastic, Antibacterial, and Anti-inflammatory Activities of Seven-membered Heterocyclic Derivatives.

Current medicinal chemistry·2022
Same author

Phillygenin Protects the Intestinal Barrier from Dysfunction via let-7b Signaling Pathway and Regulation of Intestinal Microbiota.

Journal of healthcare engineering·2022
Same author

Application of Quantitative Susceptibility Mapping in the Assessment of Iron Content in Brain Regions of Normal Children.

Current medical imaging·2022
Same journal

Dynamic inflammation-based prognostication in acute-on-chronic liver failure: The COSSH-CAR model as a step forward in personalized risk stratification.

World journal of hepatology·2026
Same journal

Epstein-Barr virus infection in children with liver transplantation.

World journal of hepatology·2026
Same journal

Effects of tenofovir amibufenamide and entecavir on estimated glomerular filtration rate in treatment-naïve patients with chronic hepatitis B.

World journal of hepatology·2026
Same journal

Fatigue and circadian rhythm in non-cirrhotic primary biliary cholangitis: An exploratory comparison with primary sclerosing cholangitis and healthy controls.

World journal of hepatology·2026
Same journal

Advances in biliary stone management: Latest-generation extracorporeal shock wave lithotripsy <i>vs</i> laser lithotripsy for difficult bile duct stones.

World journal of hepatology·2026
Same journal

Should the routine use of the 6-minute walk test be implemented in liver disease assessment: Not so fast.

World journal of hepatology·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2025

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

3.3K

Hepatitis B cure: Current situation and prospects.

Ya-Ping Li1, Chen-Rui Liu1, Ling He1

  • 1Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China.

World Journal of Hepatology
|July 1, 2024
PubMed
Summary
This summary is machine-generated.

Achieving a clinical cure for chronic hepatitis B (CHB) involves sustained viral suppression and immune control. While tailored treatments show promise, challenges like antiviral resistance and persistent viral DNA hinder a complete cure for many patients.

Keywords:
Chronic hepatitis BClinical curePolyethylene glycol interferonResearch progressTreatment strategies

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.8K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.2K

Related Experiment Videos

Last Updated: Jun 22, 2025

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

3.3K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.8K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.2K

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis B (CHB) treatment aims for clinical cure, defined as sustained virological suppression and immunological control.
  • Current guidelines recommend nucleos(t)ide analogs and/or pegylated interferon α for CHB management.
  • Tailored treatment regimens have shown success in specific patient groups.

Purpose of the Study:

  • To review current research progress in achieving a clinical cure for CHB.
  • To identify existing challenges that impede optimal treatment outcomes in CHB patients.
  • To discuss the complexities in attaining a sustained virological and immunological cure for hepatitis B.

Main Methods:

  • Literature review of current research on CHB clinical cure strategies.
  • Analysis of treatment regimens including nucleos(t)ide analogs and pegylated interferon α.
  • Examination of factors contributing to treatment challenges and suboptimal outcomes.

Main Results:

  • Tailored treatment regimens demonstrate encouraging results in select CHB patient cohorts.
  • Significant challenges persist, including antiviral resistance, incomplete immune recovery, and persistent cccDNA.
  • Variability in interferon response and lack of definitive biomarkers for treatment cessation complicate cure achievement.

Conclusions:

  • A clinical cure for CHB, defined by sustained virological suppression and immune control, remains challenging for a significant patient subset.
  • Overcoming hurdles such as drug resistance and viral persistence is crucial for advancing CHB treatment.
  • Further research is needed to develop more effective strategies and biomarkers for achieving a definitive hepatitis B cure.